Texas Instruments Forecast +4.4% as AI Demand Lifts Outlook
Can Texas Instruments turn rising AI power demand into a lasting growth story, or is this rally getting ahead of itself? Maik Kemper Editor in Chief Conclusion The…
AMD Record +5.7% as AI and Data Center Growth Fuel Shares
Is AMD’s latest surge the start of a new AI-driven breakout, or are investors already pricing in too much perfection? Maik Kemper Editor in Chief Agentic AI has…
BP Chairman Ouster Sends Shares Down 5% After Board Shock
Can BP contain the fallout from its chairman’s abrupt exit before investors start pricing in a deeper governance discount? Maik Kemper Editor in Chief Albert has helped bring…
AutoZone Earnings Drop -9% as Revenue Miss Hits Shares
Can AutoZone keep investors confident when profit beats estimates but revenue, margins, and international growth start raising tougher questions? Maik Kemper Editor in Chief I want to thank…
Micron Forecast +13.2%: UBS Sees Bigger AI Memory Upside
Can Micron’s AI memory advantage really turn a notoriously cyclical chipmaker into a premium growth story? Maik Kemper Editor in Chief We believe there’s no clear line of…
Hyperliquid Record: $1B Revenue Case Fuels ETF Boom
Is Hyperliquid’s record run a speculative squeeze, or the start of a new on-chain rival to traditional exchanges? Maik Kemper Editor in Chief Why is Hyperliquid Record important?…
Apple IMAX Acquisition: $111B Quarter Fuels Deal Debate
Could Apple turn IMAX into a prestige weapon for Apple TV+ without upsetting investors or regulators? Maik Kemper Editor in Chief Conclusion The Apple IMAX Acquisition theme is…
NVIDIA Earnings Hit $81.6B as Record Growth Meets Stock Drop
Can NVIDIA Earnings keep justifying sky-high AI expectations, or is even record growth no longer enough for Wall Street? Maik Kemper Editor in Chief Conclusion Fazit folgt. Further…
Tesla SpaceX IPO +2.6%: Why the Listing Could Shake TSLA
Could a SpaceX listing unlock Musk’s empire value while pulling fresh momentum money away from Tesla at the same time? Maik Kemper Editor in Chief Conclusion The bottom…
AbbVie MAVIRET Approval Gets EMA Backing for Acute HCV
Could AbbVie’s latest MAVIRET milestone become another quiet growth lever as investors look beyond its biggest blockbuster franchises? Maik Kemper Editor in Chief Conclusion In short, AbbVie MAVIRET…